title: Utility of uroplakin II expression as a marker of urothelial carcinoma.
abstract: Uroplakins are markers of terminally differentiated urothelium. Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0% of UC overall, including 95.7% of noninvasive UC and 65.6% of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6% of all UCs, including 96.4% of noninvasive UCs and 85.1% of INVUC, with stronger intensity and extent compared with UPII (P < .005). GATA3 labeled 2 (5%) of 38 high-grade prostate adenocarcinoma. Estrogen receptor nuclear labeling was seen in 13.0% of UCs and 12.5% of prostate carcinomas. UPII was highly specific (100%) but only moderately sensitive for UC and can therefore be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer.
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Wei
authors.initials: W
authors.lastname: Tian
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Gunes
authors.initials: G
authors.lastname: Guner
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyamoto
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Ashley
authors.initials: A
authors.lastname: Cimino-Mathews
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Nilda
authors.initials: N
authors.lastname: Gonzalez-Roibon
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Pedram
authors.initials: P
authors.lastname: Argani
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Xuan
authors.initials: X
authors.lastname: Li
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Rajni
authors.initials: R
authors.lastname: Sharma
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Andrea P
authors.initials: AP
authors.lastname: Subhawong
authors.affiliation: George Washington University, Washington DC, 20037.
authors.forename: Katayoon
authors.initials: K
authors.lastname: Rezaei
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Trinity J
authors.initials: TJ
authors.lastname: Bivalacqua
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Jonathan I
authors.initials: JI
authors.lastname: Epstein
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231.
authors.forename: Justin A
authors.initials: JA
authors.lastname: Bishop
authors.affiliation: Johns Hopkins University, Baltimore, MD, 21231. Electronic address: gnetto1@jhmi.edu.
authors.forename: George J
authors.initials: GJ
authors.lastname: Netto
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology; D002277:Carcinoma / Q000737:chemistry* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D050990:GATA3 Transcription Factor / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology; D011960:Receptors, Estrogen / Q000032:analysis; D046888:Tissue Array Analysis; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology; D060170:Uroplakin II / Q000032:analysis*; D019459:Urothelium / Q000737:chemistry* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D050990:GATA3 Transcription Factor; C494749:GATA3 protein, human; D011960:Receptors, Estrogen; C554658:UPK2 protein, human; D060170:Uroplakin II
keywords: Bladder cancer; Breast carcinoma; GATA3; Immunohistochemistry; Uroplakin II